Uncategorized

BIO 2026: Forget dual track—biopharma deals are more complex than ever

Published

on

Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version